Chewy (CHWY) Q2 2026 earnings review
Margin Extraction Shines Through a Sluggish Macro
Chewy's Q2 results tell a story of pristine execution masking a softening consumer backdrop. Revenue decelerated slightly to 7.3% YoY growth ($3.33B), yet Adjusted EBITDA surged 23.7% to $226.7M, pushing margins to an impressive 6.8%. The company’s Autoship program continues to be an impenetrable moat, now capturing 84.6% of total net sales. While active customer growth is crawling at 3.8%, management is extracting more profit per dollar through strict operational discipline and a mix shift toward high-margin healthcare. The underlying fundamentals remain so robust that management announced a raise to their full-year revenue and profitability outlook.
🐂 Bull Case
EBITDA margin expanded by 90 bps YoY to 6.8%. Chewy has proven it can structurally increase profitability even when top-line growth decelerates.
Autoship sales grew 9.3% YoY to $2.82B. It represents 84.6% of total revenue, effectively locking in recurring cash flows and insulating the business from discretionary spending shocks.
🐻 Bear Case
Active customers grew just 3.8% YoY. Without a macro recovery, top-line growth will continue to face friction as net new customer additions dry up.
Despite Net Income leaping 29.8%, Free Cash Flow reversed into a 15.5% decline YoY ($89.5M vs $105.9M) due to a sharp step-up in capital expenditures.
⚖️ Verdict: 🟢
Bullish. Chewy is executing flawlessly on the variables it can control. The macro environment is capping explosive top-line growth, but their expanding margin profile and sticky Autoship cohort make this a highly durable earnings engine.
Key Themes
Autoship is the Engine of Predictability
Autoship remains Chewy's greatest asset. Sales through the program accelerated 9.3% YoY to $2.82B, vastly outperforming the rest of the business. By pushing Autoship penetration to 84.6% of total sales (up from 83.0% last year), Chewy reduces marketing reliance, optimizes fulfillment routing, and permanently elevates the lifetime value of its base.
Structural Margin Step-Up
Chewy's profitability profile is accelerating. While Gross Margin remained stable at 30.4%, Adjusted EBITDA jumped 23.7% YoY. Operating leverage is kicking in as SG&A scales more efficiently, and the integration of high-margin healthcare services and sponsored ads provides structural tailwinds to the bottom line.
Aggressive Healthcare Expansion
Management continues to position Chewy Vet Care (CVC) as a central growth pillar. With recent acquisitions like SmartPak and Modern Animal, Chewy is aggressively building a physical and digital healthcare ecosystem to tackle a $54B TAM. Healthcare acts as both a margin-accretive revenue stream and a high-efficiency customer acquisition funnel.
Macro Pressures on Discretionary Spend
The consumer backdrop remains undeniably sluggish. Active customers grew a tepid 3.8% YoY to 21.7 million, and Net Sales Per Active Customer (NSPAC) grew a decelerating 1.9% to $602. Management had previously noted that a weakening consumer environment puts a cap on premiumization and discretionary hard-goods attachment.
Non-Autoship Sales are Shrinking
There is a stark divergence in the revenue mix. While Autoship grew 9.3%, non-Autoship sales actually fell 2.7% YoY ($513M vs $527M in 25Q2). This indicates that ad-hoc, discretionary purchases are declining, exposing Chewy's vulnerability to macro-driven consumer belt-tightening outside of core essentials.
Capital Intensity Dragging Down FCF
Free cash flow reversed, dropping 15.5% YoY to $89.5M. This directly contradicts the bullish narrative of a 23.7% surge in Adjusted EBITDA. The culprit is an aggressive 71% spike in capital expenditures ($47.9M vs $28.0M). Investors must monitor if this higher CapEx run-rate is the new normal for funding veterinary clinic rollouts.
Other KPIs
Accelerating. Grew 5.5% YoY, translating to $0.36 adjusted diluted earnings per share. This cleanly strips out $85.9 million in share-based compensation, which remains a significant recurring dilutive factor for GAAP earnings.
Stable. Up slightly by 2.6% YoY from $133.9 million in the prior year quarter, keeping liquidity ample enough to self-fund the ongoing aggressive share repurchase program.
Guidance
Accelerating. The press release stated that management is explicitly raising full-year revenue and profitability outlooks based on 'durability of recurring revenue and disciplined execution'. (Note: The exact revised ranges were deferred to the live conference call).
Key Questions
The Magnitude of the Guidance Raise
The press release announced a raise to full-year revenue and profitability. What are the specific new ranges, and how much of this upside is driven by core operations versus the integration of SmartPak and Modern Animal?
Capital Expenditure Runway
CapEx jumped 71% year-over-year, dragging down Free Cash Flow despite record EBITDA margins. What is the expected long-term CapEx percentage of sales as you build out the Chewy Vet Care physical footprint?
Non-Autoship Deterioration
Non-Autoship sales contracted year-over-year. Is this purely macro-driven pressure on discretionary goods, or is Chewy seeing increased promotional intensity from competitors in non-subscription channels?